|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Purified recombinant fragment of human CER1 expressed in E. Coli.|
|Contains||0.03% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (IHC)||1/200 - 1/1000|
|Western Blot (WB)||1/500 - 1/2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-15554 targets CER1 in IHC and WB applications and shows reactivity with Human samples.
The MA5-15554 immunogen is purified recombinant fragment of human CER1 expressed in E. Coli.
MA5-15554 detects CER1 which has a predicted molecular weight of approximately 30kDa.
This gene encodes a cytokine member of the cysteine knot superfamily, characterized by nine conserved cysteines and a cysteine knot region. The cerberus-related cytokines, together with Dan and DRM/Gremlin, represent a group of bone morphogenetic protein antagonists that can bind directly to BMPs and inhibit their activity.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Mesendogen, a novel inhibitor of TRPM6, promotes mesoderm and definitive endoderm differentiation of human embryonic stem cells through alteration of magnesium homeostasis.
MA5-15554 was used in western blot to examine the roles of TRPM6/TRPM7 channels and cellular magnesium homeostasis during development
|Geng Y,Feng B||Heliyon (1:null)||2015|
Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer.
MA5-15554 was used in immunohistochemistry - paraffin section to correlate the expressions of lung resistance protein, P-glycoprotein, multidrug resistance-associated protein (MRP)-1, MRP3, and MRP5 and histopathological parameters and clinical outcome in patients with ovarian cancer
|Sedláková I,Laco J,Caltová K,¿ervinka M,To¿ner J,¿ezá¿ A,¿pa¿ek J||International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (25:236)||2015|